Tempest Therapeutics Past Earnings Performance
Past criteria checks 0/6
Tempest Therapeutics's earnings have been declining at an average annual rate of -13.2%, while the Biotechs industry saw earnings growing at 19.1% annually.
Key information
-13.2%
Earnings growth rate
71.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -310.0% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Tempest Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -36 | 14 | 22 |
| 30 Jun 24 | 0 | -32 | 13 | 19 |
| 31 Mar 24 | 0 | -30 | 12 | 17 |
| 31 Dec 23 | 0 | -29 | 12 | 17 |
| 30 Sep 23 | 0 | -31 | 11 | 19 |
| 30 Jun 23 | 0 | -33 | 12 | 21 |
| 31 Mar 23 | 0 | -35 | 12 | 22 |
| 31 Dec 22 | 0 | -36 | 12 | 23 |
| 30 Sep 22 | 0 | -34 | 12 | 21 |
| 30 Jun 22 | 0 | -34 | 12 | 20 |
| 31 Mar 22 | 0 | -31 | 11 | 19 |
| 31 Dec 21 | 0 | -28 | 10 | 17 |
| 30 Sep 21 | 0 | -25 | 9 | 15 |
| 30 Jun 21 | 0 | -22 | 7 | 15 |
| 31 Mar 21 | 0 | -20 | 5 | 15 |
| 31 Dec 20 | 0 | -19 | 5 | 14 |
Quality Earnings: TPST is currently unprofitable.
Growing Profit Margin: TPST is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TPST is unprofitable, and losses have increased over the past 5 years at a rate of 13.2% per year.
Accelerating Growth: Unable to compare TPST's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TPST is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: TPST has a negative Return on Equity (-310.01%), as it is currently unprofitable.